Applied DNA Sciences (BNBX) AI Stock Analysis

• Market Cap: $4.51M
• Dividend Yield: N/A
• Average Volume (3M): 865.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.50
• Revenue Growth: -2.96%
• EPS Growth: 89.71%
• Country: US
• Employees: 46
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -33.41
• Shares Outstanding: 1,291,465
• 10 Day Avg. Volume: 475,004
• 30 Day Avg. Volume: 865,031
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.38
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: ―

Applied DNA Sciences faces substantial financial and operational challenges, as indicated by declining revenues and net losses. Despite some positive strategic moves, such as focusing on LineaRx, the stock suffers from poor technical indicators and valuation metrics. The company's ongoing financial struggles and the uncertainties highlighted in the earnings call contribute to a low overall stock score.

Applied DNA Sciences Business Overview & Revenue Model

Company Description

Applied DNA Sciences (APDN) is a biotechnology company specializing in DNA-based solutions. The company operates in sectors such as pharmaceuticals, textiles, and security. Its core products and services include DNA tagging, DNA-based authentication, and security solutions that help verify the originality and authenticity of products and materials.

How the Company Makes Money

Applied DNA Sciences generates revenue through the sale of its proprietary DNA-based solutions and services. The company earns money by providing DNA tagging and authentication services to businesses in various industries, including pharmaceuticals, textiles, and consumer goods. Additionally, APDN collaborates with partners in sectors like government and law enforcement to deliver security solutions. Key revenue streams include service fees for DNA tagging and authentication, as well as licensing fees from strategic partnerships. APDN's earnings are significantly influenced by its ability to secure contracts with major companies and government agencies, as well as its continued innovation in DNA technology applications.

Applied DNA Sciences Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Applied DNA Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.49
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNBX, the sentiment is Negative. The current price of 3.49 is below the 20-day moving average (MA) of 4.01, below the 50-day MA of 3.52, and below the 200-day MA of 36.97, indicating a bearish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 46.03 is Neutral, neither overbought nor oversold. The STOCH value of 3.46 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNBX.

Applied DNA Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	47 Neutral	$8.07M	―	―	―	―	―
ISPC	44 Neutral	$6.08M	―	-303.74%	―	-43.77%	55.78%
BNBX	42 Neutral	$4.51M	―	-130.75%	―	-2.96%	89.71%
INBS	38 Underperform	$9.80M	―	-186.64%	―	-1.90%	87.72%
NDRA	34 Underperform	$4.61M	―	-167.48%	―	―	77.66%

Applied DNA Sciences Corporate Events

Applied DNA Sciences Approves Reverse Stock Split

On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.